Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy

Thomas C. Greenough, Coleen K. Cunningham, Petronella Muresan, Margaret McManus, Deborah Persaud, Terry Fenton, Piers Barker, Aditya Gaur, Dennis Panicali, John L. Sullivan, Katherine Luzuriaga

Research output: Contribution to journalArticle

Abstract

A trial to evaluate the safety and immunogenicity of recombinant modified vaccinia Ankara (MVA) and fowlpox (FP) vectors expressing multiple HIV-1 proteins was conducted in twenty HIV-1 infected youth with suppressed viral replication on HAART. The MVA and FP-based multigene HIV-1 vaccines were safe and well tolerated. Increased frequencies of HIV-1 specific CD4+ proliferative responses and cytokine secreting cells were detected following immunization. Increased frequencies and breadth of HIV-1 specific CD8 T-cell responses were also detected. Plasma HIV-1-specific antibody levels and neutralizing activity were unchanged following vaccination. Poxvirus-based vaccines may merit further study in therapeutic vaccine protocols.

Original languageEnglish (US)
Pages (from-to)6883-6893
Number of pages11
JournalVaccine
Volume26
Issue number52
DOIs
StatePublished - Dec 9 2008

Keywords

  • HIV-1
  • Therapeutic immunization
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy'. Together they form a unique fingerprint.

  • Cite this

    Greenough, T. C., Cunningham, C. K., Muresan, P., McManus, M., Persaud, D., Fenton, T., Barker, P., Gaur, A., Panicali, D., Sullivan, J. L., & Luzuriaga, K. (2008). Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy. Vaccine, 26(52), 6883-6893. https://doi.org/10.1016/j.vaccine.2008.09.084